Nycomed Strikes $70 Mil. Deal To Develop Acusphere’s AI-700 In Europe
This article was originally published in The Gray Sheet
Executive Summary
Nycomed will seek European regulatory approval for Acusphere's AI-700 ultrasound contrast agent as part of a co-development and distribution deal signed between the two concerns July 7